New cream could soothe skin in rare autoimmune disease

NCT ID NCT06857240

Recruiting now Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a cream containing ruxolitinib on the skin of 15 adults with dermatomyositis whose skin symptoms haven't improved with standard treatments. The cream is applied to affected areas for up to 12 weeks to see if it reduces redness, scaling, and other signs of disease activity. The goal is to find a safer, targeted option for managing skin flares without strong pills or injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib topical cream (1.5%)
What this could lead to: If it works, this could offer a new topical treatment option for stubborn skin symptoms in dermatomyositis, potentially reducing the need for stronger systemic medications.
What could go wrong: This is a very small early-phase trial (15 people) with no placebo group, so results may not be conclusive. The cream may not work for everyone, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.